Results 41 to 50 of about 4,639 (191)
Background: Mutations in the glucocerebrosidase (GBA1) and leucine-rich repeat kinase 2 (LRRK2) genes, encoding lysosomal enzyme glucocerebrosidase (GCase) and leucine-rich repeat kinase 2 (LRRK2), respectively, are the most common related to Parkinson’s
Tatiana S. Usenko +10 more
doaj +1 more source
The presence of GBA1 gene mutations increases risk for Parkinson's disease (PD), but the pathogenic mechanisms of GBA1 associated PD remain unknown. Given that impaired α-synuclein turnover is a hallmark of PD pathogenesis and cathepsin D is a key enzyme
Shi-yu Yang +3 more
doaj +1 more source
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene, which produces the glucocerebrosidase (GCase) protein. There are more than 500 mutations reported in GBA1, among which L444P (p.Leu444Pro) and
Na Li (6550) +6 more
core +1 more source
Deregulation of mTORC1-TFEB axis in human iPSC model of GBA1-associated Parkinson’s disease
Mutations in the GBA1 gene are the single most frequent genetic risk factor for Parkinson’s disease (PD). Neurodegenerative changes in GBA1-associated PD have been linked to the defective lysosomal clearance of autophagic substrates and aggregate-prone ...
Fahad Mubariz +7 more
doaj +1 more source
Mouse and human GBA1 exhibit maximal activity at similar pH.
GBA1 in human and mouse brain lysates exhibit similar pH-dependent profile. Maximal activity of mouse GBA1 is seen at pH 4.7, maximal activity of human GBA1 is observed at pH 5.0 (value at pH 4.7 is only ~ 2% lower).
David Riddell (701428) +7 more
core +1 more source
Fluorinated Iminosugar Glycomimetics: Synthesis and Activity as GCase Ligands
DAST‐mediated deoxyfluorination of suitably functionalized piperidines provided regio‐ and stereoselective access to fluorinated piperidine and pyrrolidine glycomimetics, the latter arising from an unusual ring‐contraction process. Fluorination generally enhanced β‐glucocerebrosidase (GCase) inhibitory potency, but lost PC activity toward L444P/L444P ...
Francesca Mangiavacchi +9 more
wiley +1 more source
Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease [PDF]
Introduction: Gaucher's disease (GD) is caused by biallelic mutations in the GBA1 gene, leading to reduced glucocerebrosidase (GCase) activity and substrate (glucosylceramide and glucosylsphingosine, GlcSph) accumulation.
Di Vico, Ilaria +79 more
core +3 more sources
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies [PDF]
The discovery that patients with Gaucher Disease (GD), a rare lysosomal storage disorder, were developing symptoms similar to Parkinson's disease (PD) led to investigation of the relationship between the two seemingly unrelated pathologies. GD, an autosomal recessive disorder, is the result of a biallelic mutation in the gene GBA1, which encodes for ...
Parker H, Johnson +4 more
openaire +2 more sources
Serum phosphorylated tau 217 in variant carriers with and without Parkinson disease
It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. We evaluated levels of serum phosphorylated tau 217 (p-tau217) in samples from 29 GBA1 -PD, 32 idiopathic PD, 20 non ...
Elisa Menozzi +9 more
doaj +1 more source

